Opthea Ltd has released a press release.
Opthea Key Opinion Leader Even on Sozinibercept
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Opthea
- Opthea Corporate Presentation - March 2024
- Half Yearly Report and Accounts
- Opthea Reports Half-Year Results and Business Update
- Opthea Completes Enrollment in First Trial of Sozinibercept
- Opthea to Receive US$35M Commitment and Additional US$50M
Later from Opthea
- Opthea Corporate Presentation - April 2024
- Opthea Completes Enrollment in Phase 3 Clinical Program
- Opthea to Present at Clinical Trials at the Summit Meeting
- Trading Halt - Accelerated Offer
- Opthea Annouces Equity Raise
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea